MedTrace Logo

A Study of Enfortumab Vedotin in People With Adenoid Cystic Carcinoma

NCT06891560 · Status: RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 34

Last updated 2026-03-20

No results posted yet for this study

Summary

The purpose of this study is to find out whether enfortumab vedotin is an effective and safe treatment for people with adenoid cystic carcinoma (ACC).

Conditions

  • Adenoid Cystic Carcinoma

Interventions

DRUG

Enfortumab Vedotin

intravenously on Days 1, 8 and 15 of a 28-day cycle-dose can be done up to +/-3 days after the scheduled day of administration

Sponsors & Collaborators

Principal Investigators

  • Alan Ho, MD, PhD · Memorial Sloan Kettering Cancer Center

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-03-31
Primary Completion
2027-03-31
Completion
2027-03-31
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06891560 on ClinicalTrials.gov